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Background: Alpha fetoprotein (AFP) is an oncofetal antigen over-expressed by many hepatocellular cancers (HCC).
We previously demonstrated that HLA-A2-restricted epitopes derived from AFP are immunogenic in vitro and
in vivo despite high circulating levels of this oncofetal antigen. In order to test a more broadly applicable,
HLA-unrestricted, inexpensive, cell-free vaccine platform capable of activating tumor antigen-specific CD8+ and
CD4+ T cells, we tested full length AFP in a plasmid DNA construct in combination with an AFP-expressing
replication-deficient adenovirus (AdV) in a prime-boost vaccine strategy.
Methods: HCC patients who had an AFP+ tumor and previous treatment for HCC were screened and two patients
received vaccination with three plasmid DNA injections followed by a single AdV injection, all delivered
intramuscularly (i.m.).
Results: The vaccine was well tolerated and safe. Both patients showed immunologic evidence of immunization.
The first patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with
an AFP-expressing HCC at nine months. The second patient developed a strong AFP-specific CD8+ and CD4+
cellular response and an AdV neutralizing antibody response, and recurred at 18 months without an increase in
serum AFP.
Conclusions: The AFP DNA prime-AdV boost vaccine was safe and immunogenic. Circulating anti-AdV neutralizing
antibodies at baseline did not prohibit the development of AFP-specific cellular immunity. The patient who
developed CD8+ and CD4+ AFP-specific T cell immunity had more favorable progression-free survival. The
observations with these two patients support development of this vaccine strategy in a larger clinical trial.
Trial registration: ClinicalTrials.gov: NCT00093548
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Hepatocellular carcinoma (HCC) is one of the most
common cancers globally, with an incidence of over
600,000 new cases per year. While the majority of cases
are primarily in sub-Saharan Africa and Eastern Asia, it
is also the fastest growing cause of cancer-related death
of males in the United States (US) [1]. Within the past
30 years, the incidence and mortality rates for HCC have* Correspondence: butterfieldl@upmc.edu
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article, unless otherwise stated.tripled in the US [2]. The primary risk factors for devel-
oping HCC are cirrhosis (independent of its etiology),
and chronic infection with hepatitis B virus (HBV) or
hepatitis C virus (HCV). In the US, it is estimated that
47% of HCC cases are attributed to chronic HCV infec-
tion, with an additional 15% to HBV [3]. HBV infection
is endemic in South-East Asia and Sub-Saharan Africa,
and there is a global pandemic of HCV infection. Chronic
HCV infection likely accounts for the increased incidence
of HCC in several Western countries, where incidence has
risen to 5-20/100,000 (Spain, Italy and Greece), and to 1–
3.6/100,000 (the UK, Canada and the US) [1]. Diabetes
and obesity are also risk factors, hence HCC is expected totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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future [4].
Once diagnosed, HCC has a dismal prognosis. Small, lo-
calized tumors are potentially curable with surgery (resec-
tion and liver transplantation), however, less than 20% of
HCC patients are eligible for these procedures because
most patients have advanced disease at diagnosis or have
liver dysfunction limiting aggressive treatment [5]. Local-
regional therapy is largely palliative and includes cryoabla-
tion, radiofrequency ablation (RFA), microwave ablation,
ethanol injection and transarterial embolization (TAE).
TAE relies largely on obstruction of the hepatic artery
branches to the tumor in order to induce subsequent
tumor necrosis. HCC is resistant to chemotherapy and
other systemic treatment approaches. The multi-targeted
tyrosine kinase inhibitor, sorafenib, which improves sur-
vival by 2.3-2.8 months, is the only systemic agent found
to increase survival in patients with advanced HCC and is
currently the standard of care [6,7]. A number of other
molecularly targeted approaches, all of which target sig-
naling pathways activated in HCC, are under investigation
[7]. However, the drug-metabolizing properties of the liver,
in addition to elevated levels of multi-drug resistance pro-
teins expressed by HCC cells, likely contributes to the lim-
ited efficacy of chemotherapeutics and small molecule
drugs in the treatment of HCC [8]. Overall, however, the
median survival for patients with advanced stage, unre-
sectable HCC is less than one year [5].
Immunotherapy represents an attractive alternative to
these traditional therapies based on the sensitivity and
specificity of the immune system. While HCC is not
generally considered an “immunogenic” tumor, patients
whose tumors contain lymphocytic infiltrates show lon-
ger survival and lower risk of recurrence [9]. AFP is an
oncofetal antigen and the most abundant serum protein
in the fetus [10]. At birth, levels drop to 30–100 mg/ml
and the adult level of AFP is 1–3 ng/ml. Forty to 80% of
HCC express AFP, and serum assays play an important
role in diagnosis and monitoring responses to treatment.
Levels >20 ng/ml are generally considered abnormal,
and >200 ng/ml are specific for HCC in patients with
cirrhosis [5]. The normal biologic function of AFP is still
unknown. It has been hypothesized to play a role in the
transport of serum components, including fatty acids,
steroids, and heavy metals [11]. There have also been re-
ports of an immune suppressive role of AFP [12].
Studies in HCC patients indicate that circulating AFP-
specific T cells can be activated ex vivo and can
recognize tumor despite high circulating serum levels of
this antigen [13-17]. Polyclonal AFP-specific T cells can
also be detected in the livers of chronically infected
HCV+ and HCC patients [18]. Furthermore, elimination
of Treg can unmask AFP-specific T cells in HCC pa-
tients [19]. Importantly, AFP expression in HCC tumorcells is associated with increased tumor proliferation,
apoptosis resistance, and it is expressed in CD45−CD90+
putative HCC cancer stem cells, supporting its targeting
as a biologically relevant tumor-associated antigen [20].
Two clinical trials have been conducted testing MHC
class I-restricted peptides derived from AFP either emulsi-
fied in Montanide [14] or pulsed onto autologous DC [21].
The immunological responses detected demonstrated that
AFP peptide epitopes were immunogenic in vivo and were
able to stimulate IFNγ-producing antigen-specific CD8+ T
cells in patients with very high serum levels of AFP. In the
second trial, 10 patients (with stage III-IV disease) were
immunized and 6 showed AFP-specific T cell increases by
MHC tetramer, and 6 had increased frequency of IFN-γ-
producing, AFP-specific T cells by ELISPOT [15,21], again
demonstrating immunological activity of the AFP-based
vaccine. Two AFP peptide/DC vaccinated patients experi-
enced transient decreases in serum AFP.
In order to provide cognate CD4+ T cell help to support
CTL activity, in addition to direct activation of multiple
epitope-specific CD8+ T cells [22,23], and to eliminate
HLA-restriction requirements, we previously tested a full
length AFP strategy in a murine model. Murine AFP-
encoding plasmid DNA injection “priming” followed by a
“boost” with murine AFP-encoding AdV was performed
in an HCC tumor model [13]. This strategy was immuno-
genic, and had strong antitumor activity. Based on this
model, and other promising data on heterologous prime-
boost strategies [24], we cloned human AFP into a simple
plasmid backbone (pVAX1), and created a human AFP-
expressing AdV [25]. These AFP constructs, in addition to
a plasmid encoding human GM-CSF, were prepared to
good manufacturing practice (GMP) grade (NCI RAID
Project #176), and tested in two patients with previously
treated AFP-expressing HCC. Here we present the clinical
and immunologic outcomes of these patients receiving the
AFP DNA-prime-AdV boost vaccine.
Materials and methods
Patients
Enrollment inclusion criteria included patients 18 years
and older, with a history of AFP+ HCC, stage II-IVa, after
locoregional therapy (resection, RFA, cryoablation, ethanol
injection, chemoembolization and radioembolization),
with Karnofsky performance status ≥70%, and conserved
liver function (Child-Pugh class A or B). Exclusion criteria
included acute infection (other than HBV or HCV), HIV
infection, organ allografts, or chemotherapy or steroid
therapy in the last 30 days.
The first patients screened were excluded for: lack of
HLA-A2 positivity (the first screened patient; a criterion
later eliminated), very high levels of circulating anti-AdV
neutralizing antibodies (patients 2 and 3), early progression
(patients 2 and 4), or other non-HCC-related conditions.
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Caucasian, HBV−/HCV−, with stage II HCC and was
vaccinated between 11/2010-2/2011. Patient 8, the sec-
ond vaccinated, was female, 81 years, Caucasian, was
stage II HCC with cryptogenic cirrhosis. She was vacci-
nated between 12/2010-3/2011. Further clinical details
are presented in the Results.Vaccines
The vials of plasmid DNA (pAFP and pGM-CSF) and the
AdV (AdVhAFP) were prepared to GMP by the NCI BRB
RAID program (Stephen Creekmore, Chief), and under-
went stability testing at months 3, 6, 12 and then annually
at the SAIC Frederick, Inc. Vials were stored at −80°C in a
temperature controlled and monitored freezer in the Uni-
versity of Pittsburgh Immunologic Monitoring and Cellu-
lar Products Laboratory (IMCPL). For each vaccination,
vials were transported to the clinic on wet ice, thawed,
and drawn into syringes for intramuscular deltoid injec-
tions. Before vaccination, patients received 650 mg acet-
aminophen and 50 mg diphenhydramine. For each of the
three monthly plasmid injections, 2.5 mg of pAFP and
2.5 mg of pGM-CSF were mixed together in the syringes
before injection. For the dose of 109 pfu of AdVhAFP, the
virus was diluted in sterile saline in the IMCPL before pre-
paring the syringe for injection.Clinical assessments
All patients were presented at a weekly multi-disciplinary
Liver Tumor Board at the University of Pittsburgh Med-
ical Center and deemed eligible for the clinical trial. All
patients consented to participate in the AFP vaccine trial
which was IRB-approved by the University of Pittsburgh
Medical Center. Patients underwent routine history and
physical examination, laboratory work, and serum AFP
level. Radiologic evaluation consisted of triphasic abdom-
inal CT scan or liver MRI with contrast. Serial imaging
was done every 3–4 months after treatment. HCC recur-
rence was documented by rise in AFP level and CT/MRI
imaging showing a recurrent tumor meeting HCC criteria.Blood processing
Blood samples were transported to the IMCPL on the date
of draw immediately were processed according to labora-
tory SOPs. Serum was isolated from red top vacutainers
(BD) by centrifugation after clot formation and frozen in
aliquots at −80°C. After removal of whole blood for fresh
flow cytometry, PBMC were isolated from the green top
vacutainer tubes (BD) containing heparin via Ficoll gradi-
ents, and PBMC were cryopreserved in aliquots and
stored in liquid nitrogen vapor. Viability was 92-98% upon
thaw.Immunologic monitoring
To determine the immune status of the patients and the
effects of vaccination, peripheral blood was tested as fol-
lows in the IMCPL. All procedures followed SOPs and
included healthy donor (HD) controls.
Adenovirus ELISA
F16 Maxisorp Nunc Immuno plates were blocked with 3%
BSA/PBS, then coated with AdVLacZ at 4∙108 pfu/ml for
18–24 hours at 4˚C. Sera were thawed, serially diluted,
and plated in duplicate. Plates were incubated for 2 hours
at RT, washed 4 times, developed with rabbit anti-goat
IgG-peroxidase, and read on a Dynex MRX plate reader.
Negative control was HD serum with known low anti-
AdV antibody levels, the positive control was HD serum
with known high levels of anti-AdV antibodies, and the
standard was goat anti-human AdV antibody.
Adenovirus neutralizing antibody flow cytometry
Anti-AdV neutralizing antibodies were measured using
serial dilutions of serum (1:4 to 1:512) cultured with an in-
dicator cell line, A549 (ATCC), followed by transduction
with an AdV-encoding enhanced Green Flourescent Pro-
tein (AdVeGFP), as described [26]. The cells were tested
for the MFI of eGFP by flow cytometry. Controls included
no AdVeGFP (negative) and no serum (positive).
IFNγ ELISPOT
The IFNγ ELISPOT assay to detect AFP and AdV-
specific T cell responses was standardized with PBMC
from three HD. Responder T cell subsets were purified
before plating (CD8+, CD4+, Miltenyi Biotec). There
were no detectable baseline AFP-specific CD8+ or CD4+
T cells, and 1 of 3 HD had detectable AdV-specific CD8+
T cells, while 2 of 3 HD had AdV-specific CD4+ T cells.
Backgrounds were 0, and PMA/ionomycin positive con-
trols were >1,000 spots/105 CD8+ or CD4+ T cells.
Multi-screen HA plates (Millipore, MAHAS4510)
were coated with 4–10 ug/mL of monoclonal capture
Ab anti-human IFNγ (1-D1K, MabTech), in PBS over-
night at 4°C. After blocking the plates with RPMI/10%
AB (1 h, 4°C), CD8+ or CD4+ T cells were plated at 105
cells/well in duplicate or triplicate wells. Autologous DC
(0.5-1 × 105 well) were pulsed with different peptides
(AFP158, AFP137, AFP325, AFP542 (University of Pittsburgh
Peptide Synthesis Facility)) loaded with protein (cord
blood-derived AFP) or transduced with AdV, rinsed and
plated. Control wells contained T cells (alone or with
1 ng/mL PMA+ 1 μM ionomycin), and T cells with
unloaded DC. Cells were removed and captured cytokine
was detected by corresponding biotinylated mAb
(MabTech) at 2 μg/mL in PBS/0.5% BSA. After washing,
Avidin Peroxidase Complex (Vectastain Elite Kit) was
added for 60 min. After rinsing, peroxidase staining was
Butterfield et al. Journal of Translational Medicine 2014, 12:86 Page 4 of 9
http://www.translational-medicine.com/content/12/1/86performed with 3-amino-9-ethyl-carbazole (AEC, Sigma)
and stopped by rinsing the plates under tap water. Spot
numbers were automatically determined with Immuno-
Spot imaging system from Cellular Technology, Ltd
(Immunospot analyzer software version 5.0). To calculate
the number of responding T cells, the mean number of
spots detected with DC alone were subtracted from mean
spot numbers induced by antigen-loaded DC. A “positive”
response was considered ≥ 2x over baseline.
Serum luminex
Sera were thawed and simultaneously analyzed with the
multiplex Luminex assay (30-plex, Invitrogen) per man-
ufacturer’s protocol in a BioRad reader (IMCPL). The
following analytes were tested: GM-CSF, IFNγ, IP-10,
MCP-1, TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, and IL-
10, IL-15,IL-13, IL-17, IL-1Rα, MIP-1β, IL-2r,IL-7 Exo-
taxin, MCP-1, MIG, MIP-1alpha and RANTES, in a kit
pre-tested for any potential cross-reactivity by the manu-
facturer. Controls included the kit standard curve and
Multiplex QC standards (R&D Systems).
Flow cytometry
Whole blood was utilized for flow cytometry to deter-
mine the frequencies and phenotype of T cells, NK cells,
NK/T cells, Treg and MDSC. Blood was processed and
stained automatically per manufacturer’s instructions on
a TQ-PrepPlus2 (Beckman Coulter), and stained with
CD3, CD16, CD56, CD69, CCR7, CD4, CD25, CD39,
lineage, HLA-DR, CD14, CD11b, CD33 (Beckman
Coulter) and/or intracellular FoxP3 (eBioscience), and
analyzed on an FC500 flow cytometer using CXP v2.1
(Beckman Coulter) software.
Results
Patients
At baseline, patient 7 was free of active disease (CT
scan), had normal AFP (1 ng/ml), Karnofsky perform-
ance status of 100%, was Child-Pugh A, was HLA-A2+
and had undetectable levels of anti-AdV neutralizing
antibodies. At baseline, patient 8 was free active disease
but positive for cirrhosis, had normal AFP (5 ng/ml),
had Karnofsky performance status 80%, was Child-Pugh
A, HLA-A2+, and had intermediate detectable levels of
anti-AdV neutralizing antibodies which were in the ac-
ceptable range for trial enrollment.
Clinical cases and outcomes
Vaccinated patients had no clinically significant adverse
events. Patient 7 is an 83 year old male who underwent
laparoscopic partial right hepatic lobectomy for HCC on
1/18/07. His background liver was normal, and path-
ology confirmed a 4.5 cm moderate to poorly differenti-
ated HCC with negative margins. His pre-operativeserum AFP level was 2,168 ng/ml, and it normalized
to < 2 ng/ml post-resection. He developed a 2 cm HCC
recurrence in his liver and underwent laparoscopic ra-
diofrequency ablation (RFA) on 2/19/10 which was
37 months after his initial HCC surgical resection. Liver
biopsy at that time confirmed well-differentiated HCC
just prior to the RFA. His AFP increased to 14 ng/ml at
the time of recurrence, and normalized to 1 ng/ml post-
RFA. He received his first AFP vaccine injection on 11/
17/10 which was 46 months after his initial liver resec-
tion and 9 months after his RFA. He recurred on 8/11/
11 when liver MRI showed a new enhancing liver tumor.
This was 56 months after his initial liver resection,
19 months after his RFA, and 9 months after his first
AFP vaccine injection. His AFP level was in the normal
range at 5 ng/ml on 7/25/11. He was started on Sorafenib
therapy. His AFP remained in the normal range until 6/7/
12 when his serum AFP level increased to 98 ng/ml. It
peaked at 508 ng/ml on 11/12/12, and he was treated with
yttrium90 Theraspheres on 11/12/2012. His AFP normal-
ized to 2.5 ng/ml on 5/7/13, and remained normal at
1.9 ng/ml on 8/20/13. He is still alive as of 10-10-13.
Patient 8 is an 84 year old female who underwent lap-
aroscopic partial right hepatic lobectomy for HCC on
11/6/09. Her background liver was grossly cirrhotic, and
surgical pathology of the resected tumor confirmed a
2 cm moderately differentiated HCC with negative mar-
gins. Her pre-operative serum AFP level was 61 ng/ml,
and it normalized to 4 ng/ml post-resection. She re-
ceived her first AFP injection on 12/22/10. She had
HCC recurrence in her liver documented by CT scan on
6/6/12 which was 31 months after her liver resection,
and 18 months after the first AFP vaccine injection. Her
AFP level remained in the normal range. She was treated
with a brief course of Sorafenib, followed by observation.
Her AFP increased to 13 ng/ml on 9/25/13. She is still
alive as of 10-10-13, which is 47 months from her resec-
tion, and 34 months after the first AFP vaccine injection.
Cellular immune responses to AdV and AFP detected
CD8+ and CD4+ T cell responses to the AFP antigen and
AdV vector were tested by direct IFNγ ELISPOT at every
time point, and assays were batched to reduce assay
variability. HD did not have detectable IFNγ-producing
AFP-specific T cells, and 2 of 3 of HD had detectable
AdV-specific T cells (>10 spots/105 cells) (Additional file 1:
Figure S1). Patient 7 had AFP-specific CD4+ T cells at
baseline, but no AFP-specific CD8+ T cells (Figure 1A).
The AFP-specific CD4+ T cell frequency fluctuated
through the vaccination period, and declined during fol-
low up (d168) but did not increase with vaccination. A
low frequency of AFP-specific CD8+ T cells were only de-
tected at d168. A very low frequency response to the
HLA-A2-restricted AFP325 peptide was detected after the
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Figure 1 IFNγ ELISPOT assay testing CD8+ and CD4+ T cell responses to AFP and AdV. Patient PBMC from all time points were thawed and
batch tested by direct IFNγ ELISPOT for recognition of autologous DC alone (background), DC transduced with AdVLacZ (for AdV responses) or
co-cultured with AFP protein. Responses were also tested to HLA-A2 restricted peptides pulsed onto T2 cells (not shown). The spot counts after
background (T cells + DC alone) per 105 T cells is shown. A: Patient 7 responses are shown. Thin arrows indicate blood draws one month after
each plasmid DNA injection and the thick arrow shows the blood draw one month after the AdV boostb. B: Patient 8 responses are shown as in 1A.
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characterized AFP epitopes were not detected (not
shown). Overall, the AFP-specific immune response to
vaccination was very weak in patient 7.
Patient 7 also had detectable baseline CD4+ T cells spe-
cific to AdV, at almost 2/103 T cell frequency. These levels
were maintained through the plasmid DNA injections, but
increased after the AdV boost. A strong induction of
AdV-specific CD8+ T cells was detected at d140 and d168.
These data indicate that the intramuscularly-delivered
(i.m.) AdVhAFP was immunogenic and capable of broadly
activating a polyclonal T cell response to AdV antigens.
Patient 8 had a very different cellular response to the
vaccination regimen (Figure 1B). Her AFP-specific CD8+
and CD4+ T cell response predominated, and her min-
imal baseline AdV-specific response decreased and was
not increased with the AdVhAFP boost. Her AFP-
specific CD4+ T cell response was low at baseline, but
strongly increased after the third pAFP injection, and
remained above baseline through d168. The AFP-
specific CD8+ T cells were minimally induced by the first
two pAFP injections, but highly positive after the
AdVhAFP boost, and still high at d168. Responses to in-
dividual HLA-A2-restricted AFP peptides were not de-
tected (data not shown). These data demonstrate thatthe prime-boost regimen could induce high frequencies
of circulating AFP-specific T cells, even with a relatively
low dose of 109 AdVhAFP viral particles.
These different cellular responses may have been im-
pacted by the levels of circulating anti-AdV neutralizing
antibodies in each patient, which might influence the
ability to respond to the i.m. injected AdVhAFP boost.
Therefore, we examined both anti-AdV neutralizing
antibodies and total AdV-specific antibodies in each
patient.
Humoral immune responses to AdV were detected
Patients were initially screened for trial eligibility to ex-
clude those with very high levels of circulating anti-AdV
neutralizing antibodies. Ten HD were tested to standardize
the assay, and to identify the range of antibodies likely
to be detected (Additional file 2: Figure S2). Most donors
had detectable antibodies, 1 of 10 had high levels (pink
squares).
Interestingly, patient 7 did not have detectable anti-AdV
neutralizing antibodies (Figure 2A), and there was no in-
duction of an antibody response after AdVhAFP injection.
In contrast, patient 8 did have a detectable level of neu-
tralizing antibodies (Figure 2B). The level was stable
through pAFP injections, was boosted after the AdVhAFP
AB
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Figure 2 Serum anti-AdV neutralizing antibodies. The MFI of AdVeGFP-transduced A549 cells incubated with dilutions of serum is shown, with
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suggest that the lack of anti-AdV neutralizing antibodies
in patient 7 does not explain the limited activation of
AFP-specific T cells, and that a higher level of anti-AdV
neutralizing antibodies in no way inhibited development
of an AFP-specific cellular response in patient 8.
Total AdV-specific antibodies were also tested by ELISA.
Patients 7 and 8 had levels that were in a similar range
with other screened HCC patients and HD (Figure 3). Pa-
tient 7 had lower levels and patient 8 had higher levels0
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age of circulating T or NK cells. Differences in several
cellular subsets were detected, however it is impossible
to draw firm conclusions from the two different patients
(Additional file 3: Figure S3). Of note, patient 8 did
have a lower frequency of monocytic CD11b+/CD33+
MDSC, and higher frequencies of activated NK cells
(CD56+/CD69+), which could be examined in future
trials to determine whether these subsets are potential
immune biomarkers.
Serum cytokines, chemokines and growth factors
Patient sera was tested for a variety of cytokines, chemo-
kines and growth factors by Multiplex Luminex to iden-
tify serum biomarkers of response (Figure 4). Patient 8
had higher levels of G-CSF and CXCL10/IP-10, and
lower CXCL8/IL-8, MIP-1β, Eotaxin, RANTES, MCP-1,
EGF and HGF, relative to patient 7. Patient 8 also had a
greater increase in IL-15 than patient 7.
There was no detectable IL-2, IL-5, IL-6, IL-7, IL-13,
IL-17, TNFα, IFNγ, GM-CSF or VEGF over background
(LLD). IL-1β, IL-4, IL-10, MIP-1α and bFGF were de-
tectable but at very low levels that did not change with
vaccination. IL-12p40/p70, IL-1RA and IL-2R were de-
tected at somewhat higher levels, but also showed no
change with vaccination. These data serve to suggest
specific analytes which may be worthwhile to examine in
a larger trial.
Discussion
In this report, we present data on two previously treated
HCC patients receiving a novel DNA prime-AdV boost
vaccine to promote an AFP-specific cellular response.
Both patients were at a similar advanced age, and were
stage II HCC patients with AFP-positive tumors which
were previously treated. There were no treatment-
related toxicities observed. The dose of AdVhAFP boost1
10
100
1000
10000
B
A
S
E
LI
N
E
D
A
Y
 1
po
st
D
N
A
1
po
st
D
N
A
2
po
st
D
N
A
3
po
st
A
dV
D
A
Y
 1
40
D
A
Y
 1
68
1
pg
/m
l
patient 7
Figure 4 Multiplex serum cytokine, chemokine and growth factor ass
Luminex assay in the serum of patients 7 and 8. The levels of the 12 mostthat they received, 109 particles, was proposed as the
low dose cohort level. This dose appeared to serve as a
boost for both AFP-specific and AdV-specific T cell re-
sponses. It also boosted the level of circulating anti-AdV
neutralizing antibodies in one patient. It was not a suffi-
cient dose to promote detectable anti-AdV neutralizing
antibodies in the other patient. It is possible that 1010 or
1011 AdVhAFP particles would be a stronger boost, bet-
ter able to promote antitumor immunity (and antiviral
antibody responses) than the 109 dose.
Importantly, the presence of anti-AdV neutralizing
antibodies at baseline, and boosting the antibody level
by AdV injection, did not negatively impact AFP-specific
T cell responses, as seen in patient 8. This finding im-
plies that it might be possible to give additional boosts
of AdVhAFP to further increase T cell responses, be-
cause a single injection may not result in detectable neu-
tralizing antibody titers (patient 7), or may result in a
neutralizing antibody titer that does not block down-
stream T cell activation and expansion.
Both patients were successfully vaccinated, but patient
7 expanded only AdV-specific T cells and recurred earl-
ier with an AFP-positive tumor. Patient 8 expanded
AFP-specific T cells and anti-AdV antibodies, but had
minimal AdV-specific T cells and recurred at a later
time, with an AFP-negative tumor. These data suggest
that activation of an AFP-specific, type 1 T cell response
may have therapeutic potential and should be examined
in a larger trial. The additional immunologic assess-
ments presented also shed light on possible mechanisms
of the different outcomes of the patients. Patient 8 had
fewer CD11b+/CD33+ MDSC and more activated CD56+
NK cells at baseline, and also had a more favorable type
1 cytokine/chemokine/growth factor milieu in her
serum. These observations suggest assessments that
should be included in future studies of this vaccine
regimen.B
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essment. The levels of a broad array of analytes were tested by
highly detected analytes are graphed on a log scale in pg/ml.
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Additional file 1: Figure S1. Healthy Donor Controls: ELISPOT for AFP
and AdV-specific T Cells. To standardize the direct IFNγ ELISPOT assay for
T cell responses to AFP and AdV antigens and AFP-derived peptides, the
assays were performed with blood from 3 HD. Two of three HD have
detectable AdV-specific T cells (to AdVLacZ-transduced DC marked
“AdV”), none have spontaneous AFP-specific T cells (by AFP protein-
loaded DC or T2 cells pulsed with synthetic HLA-A2-restricted AFP-
derived peptides).
Additional file 2: Figure S2. AdV Neutralizing Antibody Assay: 9
healthy donors. To standardize the anti-AdV neutralizing antibody assay,
sera from 9 HD were tested over serial two-fold dilutions. In “week 1”, 3
donors were tested, positive and negative controls and results are shown.
The following week, 6 different donors were tested. One of the tested
donors had high levels of anti-AdV neutralizing antibodies (pink square).
Most differences between HD are in the 1:4 to 1:32 dilution range.
Additional file 3: Figure S3. Fresh flow cytometry analysis of suppressive
cells and lymphocyte subsets is shown. Whole blood was stained as
indicated to test for the circulating frequencies of MDSC small, “lymphocyte
gate” and larger “monocyte gate” CD11b+CD33+ MDSC and monocyte gate
CD14+ (HLA-DRlow MDSC), Treg (CD3+CD4+CD25highFoxP3+) and
lymphocytes (T, NK and NK/T cells). Sufficient blood was not obtained from
Patient 8 at later time points for all assays.Abbreviations
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